266 related articles for article (PubMed ID: 31236944)
41. Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment.
Arnold RS; Fedewa SA; Goodman M; Osunkoya AO; Kissick HT; Morrissey C; True LD; Petros JA
Bone; 2015 Sep; 78():81-6. PubMed ID: 25952970
[TBL] [Abstract][Full Text] [Related]
42. Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.
Lucas CG; Grenert JP; Horvai A
Arch Pathol Lab Med; 2021 Aug; 145(8):1009-1017. PubMed ID: 33147331
[TBL] [Abstract][Full Text] [Related]
43. Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.
Løvf M; Zhao S; Axcrona U; Johannessen B; Bakken AC; Carm KT; Hoff AM; Myklebost O; Meza-Zepeda LA; Lie AK; Axcrona K; Lothe RA; Skotheim RI
Eur Urol; 2019 Mar; 75(3):498-505. PubMed ID: 30181068
[TBL] [Abstract][Full Text] [Related]
44. Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time.
Rajan S; Zaccaria S; Cannon MV; Cam M; Gross AC; Raphael BJ; Roberts RD
Cancer Res Commun; 2023 Apr; 3(4):564-575. PubMed ID: 37066022
[TBL] [Abstract][Full Text] [Related]
45. Genomic Landscape of Primary and Recurrent Anal Squamous Cell Carcinomas in Relation to HPV Integration, Copy-Number Variation, and DNA Damage Response Genes.
Aldersley J; Lorenz DR; Mouw KW; D'Andrea AD; Gabuzda D
Mol Cancer Res; 2021 Aug; 19(8):1308-1321. PubMed ID: 33883185
[TBL] [Abstract][Full Text] [Related]
46. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors.
Freeman SS; Allen SW; Ganti R; Wu J; Ma J; Su X; Neale G; Dome JS; Daw NC; Khoury JD
Cancer; 2008 Sep; 113(6):1453-61. PubMed ID: 18704985
[TBL] [Abstract][Full Text] [Related]
47. Downregulation of miR-22 acts as an unfavorable prognostic biomarker in osteosarcoma.
Wang G; Shen N; Cheng L; Lin J; Li K
Tumour Biol; 2015 Sep; 36(10):7891-5. PubMed ID: 25953260
[TBL] [Abstract][Full Text] [Related]
48. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
49. Whole-exome sequencing in osteosarcoma with distinct prognosis reveals disparate genetic heterogeneity.
Liu W; Wang R; Zhang Y; Wang H; Huang Z; Jin T; Yang Y; Sun Y; Cao S; Niu X
Cancer Genet; 2021 Aug; 256-257():149-157. PubMed ID: 34153775
[TBL] [Abstract][Full Text] [Related]
50.
Sakthikumar S; Elvers I; Kim J; Arendt ML; Thomas R; Turner-Maier J; Swofford R; Johnson J; Schumacher SE; Alföldi J; Axelsson E; Couto CG; Kisseberth WC; Pettersson ME; Getz G; Meadows JRS; Modiano JF; Breen M; Kierczak M; Forsberg-Nilsson K; Marinescu VD; Lindblad-Toh K
Cancer Res; 2018 Jul; 78(13):3421-3431. PubMed ID: 29724721
[TBL] [Abstract][Full Text] [Related]
51. Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma.
Scott MC; Temiz NA; Sarver AE; LaRue RS; Rathe SK; Varshney J; Wolf NK; Moriarity BS; O'Brien TD; Spector LG; Largaespada DA; Modiano JF; Subramanian S; Sarver AL
Cancer Res; 2018 Jan; 78(2):326-337. PubMed ID: 29066513
[TBL] [Abstract][Full Text] [Related]
52. Unbiased Detection of Driver Mutations in Extramammary Paget Disease.
Ishida Y; Kakiuchi N; Yoshida K; Inoue Y; Irie H; Kataoka TR; Hirata M; Funakoshi T; Matsushita S; Hata H; Uchi H; Yamamoto Y; Fujisawa Y; Fujimura T; Saiki R; Takeuchi K; Shiraishi Y; Chiba K; Tanaka H; Otsuka A; Miyano S; Kabashima K; Ogawa S
Clin Cancer Res; 2021 Mar; 27(6):1756-1765. PubMed ID: 33323405
[TBL] [Abstract][Full Text] [Related]
53. Drivers underpinning the malignant transformation of giant cell tumour of bone.
Fittall MW; Lyskjaer I; Ellery P; Lombard P; Ijaz J; Strobl AC; Oukrif D; Tarabichi M; Sill M; Koelsche C; Mechtersheimer G; Demeulemeester J; Tirabosco R; Amary F; Campbell PJ; Pfister SM; Jones DT; Pillay N; Van Loo P; Behjati S; Flanagan AM
J Pathol; 2020 Dec; 252(4):433-440. PubMed ID: 32866294
[TBL] [Abstract][Full Text] [Related]
54. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.
Ng CKY; Bidard FC; Piscuoglio S; Geyer FC; Lim RS; de Bruijn I; Shen R; Pareja F; Berman SH; Wang L; Pierga JY; Vincent-Salomon A; Viale A; Norton L; Sigal B; Weigelt B; Cottu P; Reis-Filho JS
Clin Cancer Res; 2017 Aug; 23(15):4402-4415. PubMed ID: 28351929
[No Abstract] [Full Text] [Related]
55. DNA Mutational and Copy Number Variation Profiling of Primary Craniofacial Osteosarcomas by Next-Generation Sequencing.
Zhu GG; Lu C; Petrovic I; Nafa K; Chen W; Syed A; Rana S; Klein MJ; Huang S; Wang L; Tap WD; Ghossein RA; Shah J; Hameed MR
Head Neck Pathol; 2024 Jun; 18(1):48. PubMed ID: 38884816
[TBL] [Abstract][Full Text] [Related]
56. Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma.
Xue R; Li R; Guo H; Guo L; Su Z; Ni X; Qi L; Zhang T; Li Q; Zhang Z; Xie XS; Bai F; Zhang N
Gastroenterology; 2016 Apr; 150(4):998-1008. PubMed ID: 26752112
[TBL] [Abstract][Full Text] [Related]
57. Genomic heterogeneity of osteosarcoma - shift from single candidates to functional modules.
Poos K; Smida J; Maugg D; Eckstein G; Baumhoer D; Nathrath M; Korsching E
PLoS One; 2015; 10(4):e0123082. PubMed ID: 25848766
[TBL] [Abstract][Full Text] [Related]
58. Genome sequencing analysis of blood cells identifies germline haplotypes strongly associated with drug resistance in osteosarcoma patients.
Bhuvaneshwar K; Harris M; Gusev Y; Madhavan S; Iyer R; Vilboux T; Deeken J; Yang E; Shankar S
BMC Cancer; 2019 Apr; 19(1):357. PubMed ID: 30991985
[TBL] [Abstract][Full Text] [Related]
59. Consensus molecular subtype classification of colorectal adenomas.
Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
[TBL] [Abstract][Full Text] [Related]
60. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
